Align Technology (ALGN)
Market Price (12/24/2025): $156.72 | Market Cap: $11.3 BilSector: Health Care | Industry: Health Care Supplies
Align Technology (ALGN)
Market Price (12/24/2025): $156.72Market Cap: $11.3 BilSector: Health CareIndustry: Health Care Supplies
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 16%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14% | Weak multi-year price returns2Y Excs Rtn is -86%, 3Y Excs Rtn is -100% | Expensive valuation multiplesP/EPrice/Earnings or Price/(Net Income) is 30x |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Digital Health & Telemedicine. Themes include Personalized Diagnostics, Remote Patient Monitoring, Show more. | Key risksALGN key risks include [1] intensified competition and pricing pressure following the expiration of its key patents and [2] costly intellectual property litigation and regulatory scrutiny. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 16%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Digital Health & Telemedicine. Themes include Personalized Diagnostics, Remote Patient Monitoring, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -86%, 3Y Excs Rtn is -100% |
| Expensive valuation multiplesP/EPrice/Earnings or Price/(Net Income) is 30x |
| Key risksALGN key risks include [1] intensified competition and pricing pressure following the expiration of its key patents and [2] costly intellectual property litigation and regulatory scrutiny. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Here are key points that could explain a 10.4% movement in Align Technology's (ALGN) stock during the approximate period from August 31, 2025, to December 24, 2025:1. Better-than-Expected Q3 2025 Financial Results: Align Technology reported its third-quarter 2025 financial results on October 29, 2025, with both earnings per share (EPS) and revenue surpassing analyst expectations. The company announced an adjusted EPS of $2.61, beating the average estimate of $2.37 per share, and reported revenues of $995.7 million, exceeding the Street's forecast of $971.5 million. This strong performance typically leads to positive investor sentiment and can drive stock price increases.
2. Strong Q4 2025 Revenue Guidance: Accompanying its Q3 2025 results, Align Technology provided an optimistic outlook for the fourth quarter of 2025, projecting revenues in the range of $1.02 billion to $1.05 billion. This positive forward guidance suggests confidence in future performance and can be a significant catalyst for stock appreciation.
Show more
Stock Movement Drivers
Fundamental Drivers
The 21.5% change in ALGN stock from 9/23/2025 to 12/23/2025 was primarily driven by a 40.2% change in the company's P/E Multiple.| 9232025 | 12232025 | Change | |
|---|---|---|---|
| Stock Price ($) | 129.00 | 156.76 | 21.52% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 3964.80 | 3982.62 | 0.45% |
| Net Income Margin (%) | 11.04% | 9.50% | -13.92% |
| P/E Multiple | 21.39 | 29.98 | 40.17% |
| Shares Outstanding (Mil) | 72.56 | 72.38 | 0.26% |
| Cumulative Contribution | 21.52% |
Market Drivers
9/23/2025 to 12/23/2025| Return | Correlation | |
|---|---|---|
| ALGN | 21.5% | |
| Market (SPY) | 3.7% | 48.2% |
| Sector (XLV) | 13.2% | 44.2% |
Fundamental Drivers
The -16.0% change in ALGN stock from 6/24/2025 to 12/23/2025 was primarily driven by a -10.5% change in the company's P/E Multiple.| 6242025 | 12232025 | Change | |
|---|---|---|---|
| Stock Price ($) | 186.58 | 156.76 | -15.98% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 3980.84 | 3982.62 | 0.04% |
| Net Income Margin (%) | 10.29% | 9.50% | -7.65% |
| P/E Multiple | 33.51 | 29.98 | -10.53% |
| Shares Outstanding (Mil) | 73.56 | 72.38 | 1.61% |
| Cumulative Contribution | -16.00% |
Market Drivers
6/24/2025 to 12/23/2025| Return | Correlation | |
|---|---|---|
| ALGN | -16.0% | |
| Market (SPY) | 13.7% | 26.0% |
| Sector (XLV) | 16.4% | 48.4% |
Fundamental Drivers
The -24.5% change in ALGN stock from 12/23/2024 to 12/23/2025 was primarily driven by a -14.8% change in the company's Net Income Margin (%).| 12232024 | 12232025 | Change | |
|---|---|---|---|
| Stock Price ($) | 207.57 | 156.76 | -24.48% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 3960.52 | 3982.62 | 0.56% |
| Net Income Margin (%) | 11.15% | 9.50% | -14.78% |
| P/E Multiple | 35.13 | 29.98 | -14.65% |
| Shares Outstanding (Mil) | 74.74 | 72.38 | 3.16% |
| Cumulative Contribution | -24.55% |
Market Drivers
12/23/2024 to 12/23/2025| Return | Correlation | |
|---|---|---|
| ALGN | -24.5% | |
| Market (SPY) | 16.7% | 46.1% |
| Sector (XLV) | 13.2% | 42.7% |
Fundamental Drivers
The -23.0% change in ALGN stock from 12/24/2022 to 12/23/2025 was primarily driven by a -28.1% change in the company's Net Income Margin (%).| 12242022 | 12232025 | Change | |
|---|---|---|---|
| Stock Price ($) | 203.67 | 156.76 | -23.03% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 3864.22 | 3982.62 | 3.06% |
| Net Income Margin (%) | 13.22% | 9.50% | -28.12% |
| P/E Multiple | 31.14 | 29.98 | -3.71% |
| Shares Outstanding (Mil) | 78.09 | 72.38 | 7.32% |
| Cumulative Contribution | -23.44% |
Market Drivers
12/24/2023 to 12/23/2025| Return | Correlation | |
|---|---|---|
| ALGN | -42.3% | |
| Market (SPY) | 48.4% | 46.3% |
| Sector (XLV) | 18.2% | 38.8% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ALGN Return | 92% | 23% | -68% | 30% | -24% | -24% | -43% |
| Peers Return | 7% | 41% | -33% | -9% | -31% | -14% | -44% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 17% | 114% |
Monthly Win Rates [3] | |||||||
| ALGN Win Rate | 75% | 50% | 33% | 58% | 42% | 67% | |
| Peers Win Rate | 56% | 50% | 40% | 48% | 42% | 40% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| ALGN Max Drawdown | -51% | -7% | -73% | -13% | -26% | -40% | |
| Peers Max Drawdown | -46% | -4% | -41% | -31% | -43% | -35% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: NVST, XRAY, HSIC, DDD. See ALGN Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/23/2025 (YTD)
How Low Can It Go
| Event | ALGN | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -76.1% | -25.4% |
| % Gain to Breakeven | 318.1% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -53.8% | -33.9% |
| % Gain to Breakeven | 116.4% | 51.3% |
| Time to Breakeven | 113 days | 148 days |
| 2018 Correction | ||
| % Loss | -55.9% | -19.8% |
| % Gain to Breakeven | 126.9% | 24.7% |
| Time to Breakeven | 409 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -82.6% | -56.8% |
| % Gain to Breakeven | 474.0% | 131.3% |
| Time to Breakeven | 1,257 days | 1,480 days |
Compare to
In The Past
Align Technology's stock fell -76.1% during the 2022 Inflation Shock from a high on 9/8/2021. A -76.1% loss requires a 318.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
- Warby Parker for teeth straightening.
- Netflix for braces.
- Tesla for dental technology.
AI Analysis | Feedback
- Invisalign System: A series of custom-made, clear, removable aligners used for orthodontic treatment to gradually straighten teeth.
- iTero Intraoral Scanners: Digital scanning devices used by dental professionals to create precise 3D images of teeth and oral structures for diagnosis and treatment planning.
- exocad CAD/CAM Software: Comprehensive software solutions that enable dental professionals and labs to design and produce various dental restorations and appliances.
AI Analysis | Feedback
Align Technology (ALGN) primarily sells its products, such as the Invisalign clear aligner system and iTero intraoral scanners, to other companies in the form of dental practices and Dental Service Organizations (DSOs).
Due to the highly fragmented nature of the global dental market, Align Technology does not have a small number of "major customer companies" (e.g., large retail chains or distributors) that are publicly disclosed or individually account for a significant portion of its revenue. Instead, its customer base consists of hundreds of thousands of individual dental professionals and the organizations that manage them.
The primary categories of professional customers that Align Technology serves are:
- Orthodontists: Dental specialists who focus on correcting malocclusions (improper bites) and dental irregularities. Orthodontists are key adopters of the Invisalign system for their patients.
- General Dentists (GPs): Dental practitioners who provide a wide range of preventive, restorative, and cosmetic dental services. Align Technology has significantly expanded its efforts to train and support GPs in incorporating Invisalign treatment into their practices.
- Dental Service Organizations (DSOs): These are corporate entities that own, manage, or provide support services to multiple dental practices. Align Technology often establishes strategic partnerships and supply agreements with DSOs, which can represent a significant channel for reaching a large number of affiliated dentists and increasing product adoption across their networks. While not traditional resellers, DSOs act as a consolidated purchasing and decision-making entity for numerous practices.
AI Analysis | Feedback
nullAI Analysis | Feedback
Here is the information about the management team members of Align Technology:Joseph M. Hogan, President and Chief Executive Officer
Mr. Hogan joined Align Technology in June 2015 as President, Chief Executive Officer, and a Director. He is an accomplished chief executive with extensive experience across multiple industries including healthcare, technology, and industrial automation. Prior to Align Technology, Mr. Hogan served as CEO of ABB, a global power and automation technologies company based in Zurich, Switzerland, where he oversaw a 25% increase in revenues during his five-year tenure. Before ABB, he spent 25 years at General Electric (GE) in various executive and management roles, including eight years as CEO of GE Healthcare from 2000 to 2008, where he drove significant geographic and market portfolio expansion and more than doubled revenues from $7 billion to $16 billion.
John F. Morici, Executive Vice President, Chief Financial Officer and Global Finance
Mr. Morici joined Align Technology as Chief Financial Officer in November 2016 and is responsible for managing the company's global finance and financial strategy. Over his more than 20-year career, he has held senior leadership positions in finance, operations, and strategic planning in healthcare, medical technology, and consumer/entertainment. Prior to joining Align, Mr. Morici spent nine years at NBC Universal, where he held several senior management positions in its Universal Pictures Home Entertainment U.S. and Canadian businesses, including Chief Financial Officer, Chief Operating Officer, and most recently, Executive Vice President and Managing Director. In his role as Executive Vice President and Managing Director, he led all finance, sales, marketing, operations, and customer service organizations and was responsible for overall strategy and planning. Before NBC Universal, Mr. Morici spent eight years in senior financial management positions at GE Healthcare, including CFO for its Diagnostic Imaging and Global Products units. He also held a number of financial management roles during his tenure at Case New Holland and Abbott Laboratories.
Julie Coletti, Executive Vice President, Chief Legal and Regulatory Officer
Ms. Coletti leads Align's legal, regulatory, and quality teams and serves as corporate secretary to the Align Technology Inc.'s Board of Directors. She joined the company in May 2018 as Vice President, Associate General Counsel, Strategic Commercial Affairs, before her promotion to her current position in May 2019.
Zelko Relic, Chief Technology Officer, Executive Vice President, Global Research and Development
Mr. Relic has been the Chief Technology Officer and Executive Vice President of Align Technology since 2017. He has spent his career in the healthcare, semiconductor, and automation industries, with a track record for developing advanced technologies and solutions across global organizations. He joined the company in 2013, originally as Vice President, Research & Development. Prior to Align Technology, Mr. Relic was Vice President, Engineering for Datalogic Automation and held senior management positions in engineering at Danaher Corp, Siemens Medical Solutions USA, Kulicke&Soffa Industries, and KLA-Tencor.
Dr. Mitra Derakhshan, Executive Vice President, Chief Clinical Officer, Global Treatment Planning and Clinical Services
Dr. Derakhshan is responsible for the global clinical teams, including global treatment planning and clinical services. She has held numerous prior roles at Align Technology since August 2000, spanning clinical areas in manufacturing, R&D, international, and global marketing. She has been instrumental in many key initiatives such as product innovation, education programs, portfolio and software development, case galleries, and research studies.
AI Analysis | Feedback
Align Technology (ALGN) faces several key risks to its business:- Macroeconomic Headwinds and Softening Demand: Align Technology's business is significantly impacted by macroeconomic uncertainty, weak consumer sentiment, and a softer dental market, especially for elective dental treatments. Higher interest rates and strained consumer finances have contributed to a downturn in demand for clear aligners, leading to a shift in product mix toward lower-priced offerings and increased seasonality in sales. The company's revenues and operating margins have been dented by these factors.
- Intensified Competition and Pricing Pressure: The clear aligner market has become increasingly competitive, with the emergence of faster-scaling rivals and direct-to-consumer (DTC) competitors offering lower-priced alternatives. The expiration of several of Align Technology's key patents in 2017-2018 further intensified this competition, leading to pricing pressure, increased discounting, and erosion of profitability and margins.
- Intellectual Property Litigation and Regulatory Scrutiny: While Align Technology actively protects its intellectual property through patent infringement lawsuits against competitors, such as Angelalign Technology, these legal battles involve significant costs and inherent uncertainties. Additionally, the company has faced regulatory challenges, including inquiries into potential violations of securities law and alleged inappropriate business practices, which can intensify scrutiny and affect its reputation and demand recovery.
AI Analysis | Feedback
The increasing viability and adoption of in-office clear aligner production by dental practices represents a clear emerging threat to Align Technology.
As 3D printing technology, materials, and associated software become more sophisticated and cost-effective, dental practices and orthodontic clinics are increasingly able to produce custom clear aligners themselves. This process typically involves scanning a patient's mouth (potentially using Align's iTero scanner or other brands), using design software (Align's exocad or third-party solutions) to plan the tooth movements and design the aligner molds, and then 3D printing these molds in-house. Once printed, a plastic sheet is vacuum-formed over the mold to create the aligner.
This trend directly threatens Align Technology's core business model, which relies heavily on its centralized manufacturing and proprietary treatment planning services for Invisalign. By producing aligners in-office, practices can:
- Significantly reduce their cost per aligner, cutting into Align's manufacturing revenue and margins.
- Achieve faster turnaround times for aligner production, improving patient experience and practice efficiency.
- Gain greater control over the entire treatment planning and production process.
Companies like SprintRay, Desktop Health, and Formlabs are actively promoting and selling 3D printers and comprehensive workflows to facilitate in-office aligner fabrication, indicating a clear market shift and an emerging competitive landscape that bypasses Align's manufacturing segment.
AI Analysis | Feedback
Align Technology (ALGN) Addressable Markets:
- Invisalign Clear Aligners: The global clear aligners market, in which Invisalign is a leading product, was valued at approximately USD 6.22 billion in 2024. This market is projected to grow to USD 66.78 billion by 2033, demonstrating a Compound Annual Growth Rate (CAGR) of 30.18% from 2025 to 2033. Another estimate places the global market for Invisalign systems at USD 3.5 billion in 2023, expected to reach USD 10 billion by 2032 with a CAGR of 12.2% from 2024 to 2032. The global Invisalign braces market is anticipated to reach approximately USD 8.3 billion by the end of 2030. North America held the largest share of the clear aligners market in 2024, with a market value of USD 1.59 billion.
- iTero Intraoral Scanners: The global intraoral scanner market was valued at over USD 1.1 billion in 2024. It is projected to increase to over USD 2.2 billion by 2031, with a CAGR of 9.9%. Another report estimates the global intraoral scanner market size at USD 969.4 million in 2023, with a projection to reach USD 2,816.4 million by 2035, growing at a CAGR of 9.3% from 2024 to 2035. North America leads this market.
- exocad CAD/CAM Software: While exocad is a main product, a standalone addressable market size for only exocad software is not explicitly detailed. However, the global CAD/CAM hardware/software market (which includes exocad) was estimated to be worth approximately USD 3.22 billion (2.6 billion CHF) globally.
- Overall Consumer Market Opportunity for Align Technology: Align Technology identifies a global consumer market opportunity of 600 million potential patients worldwide that their integrated suite of products, including Invisalign, iTero, and exocad, aims to address.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Align Technology (ALGN) over the next 2-3 years:- Global Market Expansion: Align Technology is expected to continue driving revenue growth through its expansion in international markets, particularly in the Asia-Pacific (APAC), Latin America, and Europe, Middle East, and Africa (EMEA) regions. International business has consistently demonstrated stronger growth compared to the Americas and is projected to remain a significant revenue contributor.
- Product Innovation and New Product Launches: The company anticipates future revenue growth from ongoing product innovation and the introduction of new products and services. Key examples include the Invisalign Palatal Expander System and advancements in iTero Digital Solutions, such as the ClinCheck Live Plan, which automates treatment planning to enhance doctor efficiency and patient engagement.
- Growth in the Teen and Kids Segment: Expanding adoption within the teen and kids demographic is a significant driver. Align Technology has seen record-setting Invisalign case starts for younger patients, propelled by products like Invisalign First and the Palatal Expander, with this segment increasing its proportion of total shipments.
- Expansion of the Doctor Base and Digital Workflow Solutions: Increasing the global base of doctors who submit Invisalign cases and the continued adoption of digital workflow solutions are expected to fuel revenue. The company is investing in AI-powered treatment planning tools and expanding the iTero scanner ecosystem, which are designed to improve doctor adoption, operational efficiency, and patient conversion rates.
AI Analysis | Feedback
Share Repurchases
- Align Technology's Board of Directors authorized a new $1.0 billion stock repurchase program in May 2025, to be executed over the next three years.
- The company completed a prior $1.0 billion stock repurchase program on May 1, 2025, which was initially approved in January 2023.
- In fiscal year 2024, Align Technology repurchased $353 million of its common stock.
Share Issuance
- No significant new share issuances for fundraising purposes by third-parties were identified.
- Common stock issuance primarily relates to employee equity compensation plans, with stock-based compensation recorded as $154 million in 2023 and $133 million in 2022.
Outbound Investments
- In September 2023, Align Technology acquired Cubicure, a 3D printing technology and materials company, for $84.5 million.
- The company acquired Exocad Global Holdings for approximately $418.7 million in cash in March 2020, strengthening its digital dentistry platform with CAD/CAM software.
- Align Technology invested $75 million to acquire less than a 5% equity interest in Heartland Dental, a dental support organization.
Capital Expenditures
- Expected capital expenditures for fiscal year 2025 are projected to be between $100 million and $125 million, primarily for technology upgrades, manufacturing capacity, and maintenance.
- For fiscal year 2024, the company anticipated capital expenditures of approximately $100 million, focusing on building construction, improvements, and additional manufacturing capacity for international expansion.
- Capital expenditures for the nine months ended September 30, 2025, totaled $76.5 million.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to ALGN. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.0% | 21.0% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -8.8% | -8.8% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 11.5% | 11.5% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.7% | 2.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 13.8% | 13.8% | -5.1% |
| 07312025 | ALGN | Align Technology | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 23.5% | 23.5% | -3.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Align Technology
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 21.87 |
| Mkt Cap | 3.6 |
| Rev LTM | 3,624 |
| Op Inc LTM | 235 |
| FCF LTM | 262 |
| FCF 3Y Avg | 251 |
| CFO LTM | 300 |
| CFO 3Y Avg | 371 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 0.6% |
| Rev Chg 3Y Avg | 0.8% |
| Rev Chg Q | 1.8% |
| QoQ Delta Rev Chg LTM | 0.4% |
| Op Mgn LTM | 6.5% |
| Op Mgn 3Y Avg | 6.8% |
| QoQ Delta Op Mgn LTM | -0.1% |
| CFO/Rev LTM | 6.1% |
| CFO/Rev 3Y Avg | 9.6% |
| FCF/Rev LTM | 2.8% |
| FCF/Rev 3Y Avg | 5.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 3.6 |
| P/S | 0.7 |
| P/EBIT | 13.7 |
| P/E | 23.5 |
| P/CFO | 12.1 |
| Total Yield | 3.3% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 4.3% |
| D/E | 0.4 |
| Net D/E | 0.4 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 4.7% |
| 3M Rtn | 4.9% |
| 6M Rtn | 5.3% |
| 12M Rtn | -24.5% |
| 3Y Rtn | -33.8% |
| 1M Excs Rtn | 0.1% |
| 3M Excs Rtn | 2.3% |
| 6M Excs Rtn | -8.3% |
| 12M Excs Rtn | -44.4% |
| 3Y Excs Rtn | -113.0% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Clear Aligner | 3,199 | 3,073 | 3,247 | 2,101 | 2,026 |
| Systems and Services | 663 | 662 | 706 | 370 | 381 |
| Total | 3,862 | 3,735 | 3,953 | 2,472 | 2,407 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Clear Aligner | 1,182 | 1,134 | 1,326 | 768 | 836 |
| Systems and Services | 191 | 180 | 259 | 96 | 138 |
| Unallocated corporate expenses | -730 | -672 | -609 | -477 | -431 |
| Total | 643 | 643 | 976 | 387 | 542 |
Price Behavior
| Market Price | $156.76 | |
| Market Cap ($ Bil) | 11.3 | |
| First Trading Date | 01/30/2001 | |
| Distance from 52W High | -33.3% | |
| 50 Days | 200 Days | |
| DMA Price | $144.25 | $159.05 |
| DMA Trend | down | up |
| Distance from DMA | 8.7% | -1.4% |
| 3M | 1YR | |
| Volatility | 32.4% | 53.0% |
| Downside Capture | 79.70 | 175.93 |
| Upside Capture | 158.75 | 121.85 |
| Correlation (SPY) | 50.0% | 46.0% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.72 | 1.33 | 1.34 | 1.60 | 1.27 | 1.45 |
| Up Beta | 1.70 | 1.88 | 2.33 | 2.39 | 1.44 | 1.58 |
| Down Beta | -0.18 | 1.47 | 1.16 | 0.55 | 0.75 | 1.06 |
| Up Capture | 268% | 178% | 109% | 132% | 126% | 270% |
| Bmk +ve Days | 12 | 25 | 38 | 73 | 141 | 426 |
| Stock +ve Days | 9 | 22 | 29 | 65 | 119 | 370 |
| Down Capture | 163% | 73% | 119% | 222% | 137% | 110% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 10 | 19 | 33 | 59 | 128 | 379 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of ALGN With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| ALGN | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -26.3% | 14.9% | 18.8% | 72.9% | 9.0% | 3.7% | -11.4% |
| Annualized Volatility | 52.7% | 17.3% | 19.5% | 19.2% | 15.3% | 17.2% | 35.0% |
| Sharpe Ratio | -0.36 | 0.64 | 0.76 | 2.72 | 0.36 | 0.05 | -0.14 |
| Correlation With Other Assets | 42.1% | 45.7% | 2.0% | 16.1% | 41.1% | 29.1% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of ALGN With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| ALGN | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -21.2% | 8.4% | 14.8% | 18.9% | 11.8% | 4.7% | 35.5% |
| Annualized Volatility | 49.6% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.9% |
| Sharpe Ratio | -0.29 | 0.40 | 0.70 | 0.98 | 0.51 | 0.16 | 0.62 |
| Correlation With Other Assets | 40.6% | 53.5% | 5.7% | 11.5% | 42.8% | 24.7% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of ALGN With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| ALGN | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 9.1% | 9.9% | 14.8% | 15.1% | 6.8% | 5.4% | 69.1% |
| Annualized Volatility | 48.7% | 16.6% | 18.0% | 14.8% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.37 | 0.49 | 0.71 | 0.85 | 0.31 | 0.23 | 0.90 |
| Correlation With Other Assets | 48.4% | 55.9% | 3.9% | 17.7% | 44.2% | 15.6% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/29/2025 | 4.9% | 4.0% | 11.2% |
| 7/30/2025 | -36.6% | -32.8% | -30.7% |
| 4/30/2025 | 2.0% | -0.6% | 4.4% |
| 2/5/2025 | 0.9% | -5.1% | -19.7% |
| 10/23/2024 | 4.2% | 1.5% | 9.9% |
| 7/24/2024 | -7.7% | -5.3% | -6.6% |
| 4/24/2024 | -1.0% | -9.3% | -19.6% |
| 1/31/2024 | 2.3% | 6.5% | 12.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 13 | 12 | 11 |
| # Negative | 11 | 12 | 13 |
| Median Positive | 4.9% | 8.5% | 11.2% |
| Median Negative | -7.7% | -8.3% | -13.5% |
| Max Positive | 35.0% | 30.9% | 31.4% |
| Max Negative | -36.6% | -32.8% | -30.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11052025 | 10-Q 9/30/2025 |
| 6302025 | 8062025 | 10-Q 6/30/2025 |
| 3312025 | 5082025 | 10-Q 3/31/2025 |
| 12312024 | 2282025 | 10-K 12/31/2024 |
| 9302024 | 11052024 | 10-Q 9/30/2024 |
| 6302024 | 8022024 | 10-Q 6/30/2024 |
| 3312024 | 5032024 | 10-Q 3/31/2024 |
| 12312023 | 2282024 | 10-K 12/31/2023 |
| 9302023 | 11032023 | 10-Q 9/30/2023 |
| 6302023 | 8042023 | 10-Q 6/30/2023 |
| 3312023 | 5052023 | 10-Q 3/31/2023 |
| 12312022 | 2272023 | 10-K 12/31/2022 |
| 9302022 | 11042022 | 10-Q 9/30/2022 |
| 6302022 | 8042022 | 10-Q 6/30/2022 |
| 3312022 | 5052022 | 10-Q 3/31/2022 |
| 12312021 | 2252022 | 10-K 12/31/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.